AVB-307

AVB-307 is an investigational adeno-associated virus (AAV)-based optogenetic gene therapy being developed by AviadoBio for the treatment of inherited retinal diseases (IRDs). The therapy utilizes optogenetics to restore vision by delivering a gene encoding a light-sensitive protein (opsin) to specific retinal cells, such as bipolar or ganglion cells, effectively turning them into functional photoreceptors. This approach is designed to be mutation-agnostic, potentially benefiting patients with various forms of advanced retinal degeneration where photoreceptor cells have been lost but the downstream neural architecture remains intact. AVB-307 is intended to be delivered via intravitreal injection and aims to provide a durable, one-time treatment to restore light sensitivity and visual perception.